Main Article Content
Part I: Metformin nanoparticles were created using a system of W/O microemulsions, ZnO nanoparticles were synthesized using a photo-irradiation approach, and metformin nanoparticles were loaded onto zinc oxide nanoparticles using a density function theory study and UV-visible. X-ray diffraction (XRD) and transmission electron microscope (TEM) were used to diagnose previously prepared nanoparticles, and these techniques revealed that the average size of previously prepared nanoparticles is (25.69-40.58) nm.
Part II: The goal of this study was to see if ZnO nanoparticles loaded with metformin nanoparticles could ameliorate the glycemic state of type 2 diabetic rats. A high-fat diet combined with a single dosage of 30 mg/kg streptozotocin was used to successfully develop type 2 diabetes in rats. ZnO nanoparticles loaded with metformin nanoparticles was administered intragastrically for 60 days, and fasting blood sugar, fasting insulin concentration, Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), C- Peptide and HbA1c were subsequently examined at the end of administration. The results of the current study indicated that therapy ZnO NPs loaded with metformin NPs effectively reducedthe levels of fasting blood sugar, fasting insulin concentration, Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), C- Peptide and HbA1c in rats with T2D. This indicates that therapy with (ZnO NPs Loaded with Metformin NPs) is helpful in reducing side effects and improving type 2 diabetes compliance.